Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Abbott/Vysis PathVysion HER-2 Test Labeling Cleared To Carry Herceptin

This article was originally published in The Gray Sheet

  • News

Executive Summary

Vysis will file an amendment to its PathVysion PMA to include retrospective outcome data from Genentech comparing the fluorescence in situ hybridization (FISH) test with immunohistochemistry (IHC) in its product labeling

You may also be interested in...



Dako Augments Diagnostic/Drug Tandem Strategy Post-Merger

DakoCytomation will develop an epidermal growth factor (EGF) receptor diagnostic kit to work in tandem with a cancer drug that blocks EGF receptors

Dako Augments Diagnostic/Drug Tandem Strategy Post-Merger

DakoCytomation will develop an epidermal growth factor (EGF) receptor diagnostic kit to work in tandem with a cancer drug that blocks EGF receptors

Test Would Assess Risk Of Cardiovascular Disease Using Enzyme’s Presence

diaDexus and GlaxoSmithKline are in the early stages of developing a joint diagnostic and therapeutic approach to treat patients by detecting and inhibiting an enzyme that may predict instances of cardiovascular disease

Table

View full table

Related Content

Medtech Insight
Medtech Insight
Tags:
Latest Headlines

GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

See All
UsernamePublicRestriction

Register

MT015916

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By